Biofrontera Inc (BFRI) FinancialsBFRIBiofrontera Inc

Evaluating the bottom line, Biofrontera Inc maintains a gross margin of 79.92%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4.37%, while the net margin is -5.03%. These profitability ratios, combined with a Return on Equity (ROE) of -988.35%, provide a clear picture of how effectively BFRI converts its operational activities into shareholder value.

In the context of the broader market, BFRI competes directly with industry leaders such as IMRN and CNSY. With a market capitalization of $12.33M, it holds a leading position in the sector. When comparing efficiency, BFRI's gross margin of 79.92% stands against IMRN's 63.42% and CNSY's 100.00%. Such benchmarking helps identify whether Biofrontera Inc is trading at a premium or discount relative to its financial performance.

Biofrontera has shown a gross margin of 79.92% in Q2 2026, indicating strong profitability potential. However, it has also reported a net income loss of $604,000 in the same quarter, reflecting ongoing challenges in achieving profitability.